|
WO2019071270A1
|
|
Pharmaceutical compositions
|
|
WO2019071272A1
|
|
Pharmaceutical compositions for the treatment of the attention-deficit/hyperactivity disorder (adhd)
|
|
US2019060287A1
|
|
Tizanidine formulations
|
|
CA3050119A1
|
|
Cysteamine prodrugs
|
|
TW201808304A
|
|
Methods of treating eosinophilic esophagitis
|
|
US2018256515A1
|
|
Oral amphetamine composition
|
|
AU2016213816A1
|
|
Orally administered corticosteroid compositions
|
|
AU2014233629A1
|
|
Orally administered corticosteroid compositions
|
|
AU2013273835A1
|
|
Timed, pulsatile release systems
|
|
US2014134246A1
|
|
Rapid dissolve tablet compositions for vaginal administration
|
|
TW201006509A
|
|
Compositions comprising weakly basic drugs and controlled-release dosage forms
|
|
TW200911267A
|
|
Orally disintegrating tablet compositions of lamotrigine
|
